Valproic Acid

Generic name: Pronounced as (val proe' ik)
Brand names
  • Depakene®
  • Depakote®
  • Depakote® ER
  • Depakote® Sprinkle
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 04/15/2019

Divalproex sodium, valproate sodium, and valproic acid, are all similar medications that are used by the body as valproic acid. Therefore, the term valproic acid will be used to represent all of these medications in this discussion.

Valproic acid may cause serious or life-threatening damage to the liver that is most likely to occur within the first 6 months of therapy. The risk of developing liver damage is greater in children who are younger than 2 years of age and are also taking more than one medication to prevent seizures, have certain inherited diseases that may prevent the body from changing food to energy normally, or any condition that affects the ability to think, learn, and understand. Tell your doctor if you have a certain inherited condition that affects the brain, muscles, nerves, and liver (Alpers Huttenlocher Syndrome), urea cycle disorder (an inherited condition that affects the ability to metabolize protein), or liver disease. Your doctor will probably tell you not to take valproic acid. If you notice that your seizures are more severe or happen more often or if you experience any of the following symptoms, call your doctor immediately: excessive tiredness, lack of energy, weakness, pain on the right side of your stomach, loss of appetite, nausea, vomiting,, dark urine, yellowing of your skin or the whites of your eyes, or swelling of the face.

Valproic acid can cause serious birth defects (physical problems that are present at birth), especially affecting the brain and spinal cord and can also cause lower intelligence and problems with movement and coordination, learning, communication, emotions, and behavior in babies exposed to valproic acid before birth. Tell your doctor if you are pregnant or plan to become pregnant. Women who are pregnant or who are able to become pregnant and are not using effective birth control must not take valproic acid to prevent migraine headaches. Women who are pregnant should only take valproic acid to treat seizures or bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods) if other medications have not successfully controlled their symptoms or cannot be used. Talk to your doctor about the risks of using valproic acid during pregnancy. If you are a woman of childbearing age, including girls from the start of puberty, talk to your doctor about using other possible treatments instead of valproic acid. If the decision is made to use valproic acid, you must use effective birth control during your treatment. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking valproic acid, call your doctor immediately. Valproic acid can harm the fetus.

Valproic acid may cause serious or life-threatening damage to the pancreas. This may occur at any time during your treatment. If you experience any of the following symptoms, call your doctor immediately: ongoing pain that begins in the stomach area but may spread to the back nausea, vomiting, or loss of appetite.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to valproic acid.

Talk to your doctor about the risks of taking valproic acid or of giving valproic acid to your child.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with valproic acid and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Valproic acid is used alone or with other medications to treat certain types of seizures. Valproic acid is also used to treat mania (episodes of frenzied, abnormally excited mood) in people with bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). It is also used to prevent migraine headaches but not to relieve headaches that have already begun. Valproic acid is in a class of medications called anticonvulsants. It works by increasing the amount of a certain natural substance in the brain.

Valproic acid comes as a capsule, an extended-release (long-acting) tablet, a delayed-release (releases the medication in the intestine to prevent damage to the stomach) tablet, a sprinkle capsule (capsule that contains small beads of medication that can be sprinkled on food), and a syrup (liquid) to take by mouth. The syrup, capsules, delayed-release tablets, and sprinkle capsules are usually taken two or more times daily. The extended-release tablets are usually taken once a day. Take valproic acid at around the same time(s) every day. Take valproic acid with food to help prevent the medication from upsetting your stomach. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take valproic acid exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the regular capsules, delayed-release capsule, and extended-release tablets whole; do not split, chew, or crush them.

You can swallow the sprinkle capsules whole, or you can open the capsules and sprinkle the beads they contain on a teaspoonful of soft food, such as applesauce or pudding. Swallow the mixture of food and medication beads right after you prepare it. Be careful not to chew the beads. Do not store unused mixtures of food and medication.

Do not mix the syrup into any carbonated drink.

Divalproex sodium, valproate sodium, and valproic acid products are absorbed by the body in different ways and cannot be substituted for one another. If you need to switch from one product to another, your doctor may need to adjust your dose. Each time you receive your medication, check to be sure that you have received the product that was prescribed for you. Ask your pharmacist if you are not sure that you received the right medication.

Your doctor may start you on a low dose of valproic acid and gradually increase your dose.

Valproic acid may help to control your condition but will not cure it. Continue to take valproic acid even if you feel well. Do not stop taking valproic acid without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood or if you find out that you are pregnant. If you suddenly stop taking valproic acid, you may experience a severe, long-lasting and possibly life-threatening seizure. Your doctor will probably decrease your dose gradually.

Valproic acid is also sometimes used to treat outbursts of aggression in children with attention deficit hyperactivity disorder (ADHD; more difficulty focusing or remaining still or quiet than other people who are the same age). Talk to your doctor about the possible risks of using this medication for your condition.

This medication is sometimes prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking valproic acid,

  • tell your doctor and pharmacist if you are allergic to valproic acid, any other medications, or any of the ingredients in the type of valproic acid that has been prescribed for you. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: acyclovir (Zovirax), anticoagulants ('blood thinners') such as warfarin (Coumadin), amitriptyline, aspirin, carbamazepine (Tegretol), cholestyramine (Prevalite), clonazepam (Klonopin), diazepam (Valium), doripenem (Doribax), ertapenem (Invanz), ethosuximide (Zarontin), felbamate (Felbatol), certain hormonal contraceptives (birth control pills, rings, patches, implants, injections, and intrauterine devices), imipenem and cilastatin (Primaxin), lamotrigine (Lamictal),medications for anxiety or mental illness, meropenem (Merrem), nortriptyline (Pamelor), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin), rufinamide (Banzel), sedatives, sleeping pills, tolbutamide, topiramate (Topamax),tranquilizers,and zidovudine (Retrovir). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had episodes of confusion and loss of ability to think and understand, especially during pregnancy or childbirth; coma (loss of consciousness for a period of time); difficulty coordinating your movements; human immunodeficiency virus (HIV); or cytomegalovirus (CMV; a virus that can cause symptoms in people who have weak immune systems).

  • tell your doctor if you are breastfeeding.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking valproic acid.

  • you should know that valproic acid may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • remember that alcohol can add to the drowsiness caused by this medication.

  • you should know that valproic acid can cause extreme drowsiness that may cause you to eat or drink less than you normally would, especially if you are elderly. Tell your doctor if you are not able to eat or drink as you normally do.

  • you should know that your mental health may change in unexpected ways and you may become suicidal (thinking about harming or killing yourself or planning or trying to do so) while you are taking valproic acid for the treatment of epilepsy, mental illness, or other conditions. A small number of adults and children 5 years of age and older (about 1 in 500 people) who took anticonvulsants such as valproic acid to treat various conditions during clinical studies became suicidal during their treatment. Some of these people developed suicidal thoughts and behavior as early as one week after they started taking the medication. There is a risk that you may experience changes in your mental health if you take an anticonvulsant medication such as valproic acid, but there may also be a risk that you will experience changes in your mental health if your condition is not treated. You and your doctor will decide whether the risks of taking an anticonvulsant medication are greater than the risks of not taking the medication. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: panic attacks; agitation or restlessness; new or worsening irritability, anxiety, or depression; acting on dangerous impulses; difficulty falling or staying asleep; aggressive, angry, or violent behavior; mania (frenzied, abnormally excited mood); talking or thinking about wanting to hurt yourself or end your life; withdrawing from friends and family; preoccupation with death and dying; giving away prized possessions; or any other unusual changes in behavior or mood. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Valproic acid may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • drowsiness

    • dizziness

    • headache

    • diarrhea

    • constipation

    • changes in appetite

    • weight changes

    • back pain

    • agitation

    • mood swings

    • abnormal thinking

    • uncontrollable shaking of a part of the body

    • problems with walking or coordination

    • uncontrollable movements of the eyes

    • blurred or double vision

    • ringing in the ears

    • hair loss

  • Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS section, call your doctor immediately:

    • unusual bruising or bleeding

    • tiny purple or red spots on the skin

    • fever

    • rash

    • bruising

    • hives

    • difficulty breathing or swallowing

    • swollen glands

    • swelling of face, eyes, lips, tongue, or throat

    • peeling or blistering skin

    • confusion

    • tiredness

    • vomiting

    • drop in body temperature

    • weakness or swelling in the joints

  • Valproic acid may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature, away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • sleepiness

  • irregular heartbeat

  • coma (loss of consciousness for a period of time)

If you are taking the sprinkle capsules, you may notice the medication beads in your stool. This is normal and does not mean that you did not get the full dose of medication.

If you have diabetes and your doctor has told you to test your urine for ketones, tell the doctor that you are taking valproic acid. Valproic acid can cause false results on urine tests for ketones.

Before having any laboratory test, tell your doctor and the laboratory personnel that you are taking valproic acid.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • Divalproex sodium
  • Valproate sodium

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic acid.
Repaglinide Repaglinide The metabolism of Repaglinide can be decreased when combined with Valproic acid.
Montelukast Montelukast The metabolism of Montelukast can be decreased when combined with Valproic acid.
Leflunomide Leflunomide The metabolism of Leflunomide can be decreased when combined with Valproic acid.
Delavirdine Delavirdine The metabolism of Valproic acid can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Nevirapine can be increased when combined with Valproic acid.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Valproic acid.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Valproic acid.
Acitretin Acitretin Valproic acid may increase the Pseudotumor Cerebri activities of Acitretin.
Alitretinoin Alitretinoin Valproic acid may increase the Pseudotumor Cerebri activities of Alitretinoin.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Valproic acid.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Valproic acid.
Candesartan Candesartan The metabolism of Candesartan can be decreased when combined with Valproic acid.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Valproic acid.
Clopidogrel Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Valproic acid.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Valproic acid is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Valproic acid.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The excretion of Valproic acid can be decreased when combined with Conjugated estrogens.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Valproic acid.
Guanfacine Guanfacine The serum concentration of Valproic acid can be increased when it is combined with Guanfacine.
Mycophenolate Mycophenolate The metabolism of Mycophenolic acid can be decreased when combined with Valproic acid.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Valproic acid is combined with Naratriptan.
Olsalazine Olsalazine The serum concentration of Valproic acid can be increased when it is combined with Olsalazine.
Paregoric Paregoric The metabolism of Morphine can be decreased when combined with Valproic acid.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Valproic acid.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Valproic acid is combined with Pentazocine.
Prednisone Prednisone The metabolism of Valproic acid can be increased when combined with Prednisone.
Ranitidine Ranitidine The excretion of Ranitidine can be decreased when combined with Valproic acid.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Valproic acid.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Valproic acid is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Valproic acid is combined with Sumatriptan.
Tacrolimus Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Valproic acid.
Tizanidine Tizanidine The metabolism of Valproic acid can be decreased when combined with Tizanidine.
Zolmitriptan Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Valproic acid.
Famotidine Injection Famotidine Injection The excretion of Valproic acid can be decreased when combined with Famotidine.
Fluconazole Injection Fluconazole Injection The metabolism of Valproic acid can be decreased when combined with Fluconazole.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Valproic acid.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Hydromorphone.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Valproic acid.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Valproic acid.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Valproic acid.
Morphine Injection Morphine Injection The metabolism of Morphine can be decreased when combined with Valproic acid.
Zidovudine Injection Zidovudine Injection The serum concentration of Zidovudine can be increased when it is combined with Valproic acid.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Valproic acid.
Cyclosporine Cyclosporine The metabolism of Valproic acid can be decreased when combined with Cyclosporine.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Valproic acid.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Valproic acid.
Torsemide Torsemide The metabolism of Torasemide can be decreased when combined with Valproic acid.
Olanzapine Olanzapine The serum concentration of Olanzapine can be decreased when it is combined with Valproic acid.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Valproic acid is combined with Alosetron.
Dofetilide Dofetilide The metabolism of Dofetilide can be decreased when combined with Valproic acid.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Valproic acid is combined with Entacapone.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Valproic acid can be decreased when used in combination with Hydroxychloroquine.
Meloxicam Meloxicam The protein binding of Valproic acid can be decreased when combined with Meloxicam.
Orlistat Orlistat Orlistat can cause a decrease in the absorption of Valproic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxcarbazepine Oxcarbazepine The serum concentration of the active metabolites of Valproic acid can be decreased when Valproic acid is used in combination with Oxcarbazepine.
Pantoprazole Pantoprazole The excretion of Valproic acid can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan The metabolism of Valproic acid can be decreased when combined with Telmisartan.
Temozolomide Temozolomide The risk or severity of adverse effects can be increased when Valproic acid is combined with Temozolomide.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Valproic acid is combined with Zaleplon.
Anakinra Anakinra The metabolism of Valproic acid can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Valproic acid.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Valproic acid.
Trimipramine Trimipramine The metabolism of Valproic acid can be decreased when combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Valproic acid can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Valproic acid can be decreased when combined with Armodafinil.
Tenofovir Tenofovir The excretion of Tenofovir can be decreased when combined with Valproic acid.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The protein binding of Valproic acid can be decreased when combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Valproic acid.
Epinephrine Injection Epinephrine Injection The metabolism of Valproic acid can be decreased when combined with Epinephrine.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Valproic acid.
Adalimumab Injection Adalimumab Injection The metabolism of Valproic acid can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Valproic acid.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Valproic acid.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Valproic acid is combined with Dexmethylphenidate.
Ezetimibe Ezetimibe The metabolism of Ezetimibe can be decreased when combined with Valproic acid.
Atazanavir Atazanavir The metabolism of Valproic acid can be decreased when combined with Atazanavir.
Almotriptan Almotriptan The metabolism of Almotriptan can be decreased when combined with Valproic acid.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Valproic acid.
Mefloquine Mefloquine The therapeutic efficacy of Valproic acid can be decreased when used in combination with Mefloquine.
Rosuvastatin Rosuvastatin The excretion of Rosuvastatin can be decreased when combined with Valproic acid.
Vardenafil Vardenafil The metabolism of Vardenafil can be decreased when combined with Valproic acid.
Alfuzosin Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Valproic acid.
Aprepitant Aprepitant The metabolism of Valproic acid can be decreased when combined with Aprepitant.
Memantine Memantine The metabolism of Valproic acid can be decreased when combined with Memantine.
Tegaserod Tegaserod The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tegaserod.
Frovatriptan Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Valproic acid.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Valproic acid.
Progesterone Progesterone The metabolism of Valproic acid can be increased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Valproic acid.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valproic acid.
Infliximab Injection Infliximab Injection The metabolism of Valproic acid can be increased when combined with Infliximab.
Oxandrolone Oxandrolone The metabolism of Valproic acid can be decreased when combined with Oxandrolone.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Valproic acid is combined with Protriptyline.
Rifaximin Rifaximin The metabolism of Valproic acid can be increased when combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Valproic acid is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Norethisterone can be increased when combined with Valproic acid.
Trospium Trospium Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan The metabolism of Bosentan can be decreased when combined with Valproic acid.
Cefditoren Cefditoren The excretion of Cefdinir can be decreased when combined with Valproic acid.
Cinacalcet Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Valproic acid.
Erlotinib Erlotinib The metabolism of Valproic acid can be decreased when combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Valproic acid is combined with Eszopiclone.
Ganciclovir Ganciclovir The excretion of Valproic acid can be decreased when combined with Ganciclovir.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Valproic acid.
Valganciclovir Valganciclovir The therapeutic efficacy of Valproic acid can be decreased when used in combination with Valganciclovir.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Valproic acid.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Valproic acid.
Entecavir Entecavir The metabolism of Entecavir can be decreased when combined with Valproic acid.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Valproic acid can be increased when combined with Peginterferon alfa-2b.
Sodium Oxybate Sodium Oxybate The serum concentration of Sodium oxybate can be increased when it is combined with Valproic acid.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic acid.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Valproic acid is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Valproic acid is combined with Ramelteon.
Darifenacin Darifenacin Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Valproic acid.
Deferasirox Deferasirox The metabolism of Valproic acid can be decreased when combined with Deferasirox.
Tipranavir Tipranavir The metabolism of Valproic acid can be increased when combined with Tipranavir.
Felbamate Felbamate The serum concentration of Valproic acid can be increased when it is combined with Felbamate.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Valproic acid.
Abatacept Injection Abatacept Injection The metabolism of Valproic acid can be increased when combined with Abatacept.
Rasagiline Rasagiline The metabolism of Rasagiline can be decreased when combined with Valproic acid.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imatinib.
Sitagliptin Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Valproic acid.
Gefitinib Gefitinib The metabolism of Valproic acid can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Valproic acid.
Paliperidone Paliperidone The serum concentration of Paliperidone can be increased when it is combined with Valproic acid.
Bortezomib Bortezomib The metabolism of Valproic acid can be decreased when combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The excretion of Clofarabine can be decreased when combined with Valproic acid.
Fulvestrant Injection Fulvestrant Injection The metabolism of Fulvestrant can be decreased when combined with Valproic acid.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Valproic acid.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Valproic acid.
Bismuth Subsalicylate Bismuth Subsalicylate The serum concentration of Valproic acid can be increased when it is combined with Bismuth subsalicylate.
Pemetrexed Injection Pemetrexed Injection The excretion of Pemetrexed can be decreased when combined with Valproic acid.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Valproic acid.
Lisdexamfetamine Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Valproic acid.
Vorinostat Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Valproic acid is combined with Vorinostat.
Sorafenib Sorafenib The metabolism of Valproic acid can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The metabolism of Valproic acid can be decreased when combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Valproic acid.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Valproic acid.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Valproic acid.
Mexiletine Mexiletine The metabolism of Mexiletine can be decreased when combined with Valproic acid.
Armodafinil Armodafinil The metabolism of Valproic acid can be decreased when combined with Armodafinil.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Valproic acid.
Antipyrine-Benzocaine Otic Antipyrine-Benzocaine Otic The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Benzocaine.
Nilotinib Nilotinib The metabolism of Valproic acid can be decreased when combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Toremifene.
Raltegravir Raltegravir The metabolism of Raltegravir can be decreased when combined with Valproic acid.
Bexarotene Bexarotene Valproic acid may increase the Pseudotumor Cerebri activities of Bexarotene.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Valproic acid can be decreased when combined with Chloramphenicol.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Valproic acid.
Doripenem Injection Doripenem Injection The therapeutic efficacy of Valproic acid can be decreased when used in combination with Doripenem.
Etravirine Etravirine The metabolism of Etravirine can be decreased when combined with Valproic acid.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Valproic acid is combined with Desvenlafaxine.
Nebivolol Nebivolol The metabolism of Nebivolol can be decreased when combined with Valproic acid.
Tretinoin Tretinoin Valproic acid may increase the Pseudotumor Cerebri activities of Tretinoin.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Valproic acid.
Leucovorin Injection Leucovorin Injection The serum concentration of Leucovorin can be decreased when it is combined with Valproic acid.
Pilocarpine Pilocarpine The metabolism of Valproic acid can be decreased when combined with Pilocarpine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Valproic acid.
Certolizumab Injection Certolizumab Injection The metabolism of Valproic acid can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Valproic acid.
Irinotecan Injection Irinotecan Injection The risk or severity of neutropenia can be increased when Valproic acid is combined with Irinotecan.
Levoleucovorin Injection Levoleucovorin Injection The serum concentration of Levoleucovorin can be decreased when it is combined with Valproic acid.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Valproic acid.
Rufinamide Rufinamide The serum concentration of Rufinamide can be increased when it is combined with Valproic acid.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Valproic acid.
Naltrexone Injection Naltrexone Injection The metabolism of Naltrexone can be decreased when combined with Valproic acid.
Eltrombopag Eltrombopag The metabolism of Valproic acid can be decreased when combined with Eltrombopag.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Valproic acid is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Valproic acid.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Valproic acid can be decreased when used in combination with Sodium phosphate, monobasic.
Fesoterodine Fesoterodine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Valproic acid.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Valproic acid.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Valproic acid.
Prasugrel Prasugrel The metabolism of Prasugrel can be decreased when combined with Valproic acid.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Valproic acid is combined with Lacosamide.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Valproic acid.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Valproic acid.
Dronedarone Dronedarone Valproic acid may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Palonosetron.
Saxagliptin Saxagliptin The excretion of Saxagliptin can be decreased when combined with Valproic acid.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Valproic acid.
Romidepsin Injection Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Valproic acid.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Topotecan Topotecan Valproic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Golimumab Injection Golimumab Injection The metabolism of Valproic acid can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Valproic acid can be decreased when combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Valproic acid is combined with Vigabatrin.
Pitavastatin Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Valproic acid.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Valproic acid.
Ulipristal Ulipristal The metabolism of Ulipristal can be increased when combined with Valproic acid.
Levonorgestrel Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Valproic acid.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Valproic acid can be increased when combined with Tocilizumab.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Valproic acid.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Valproic acid.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Valproic acid is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Acetaminophen.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Valproic acid is combined with Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Valproic acid.
Busulfan Injection Busulfan Injection The metabolism of Busulfan can be decreased when combined with Valproic acid.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Valproic acid.
Linagliptin Linagliptin The metabolism of Linagliptin can be decreased when combined with Valproic acid.
Rilpivirine Rilpivirine The metabolism of Valproic acid can be decreased when combined with Rilpivirine.
Telaprevir Telaprevir The metabolism of Valproic acid can be decreased when combined with Glecaprevir.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Valproic acid can be decreased when combined with Cyclophosphamide.
Abiraterone Abiraterone The metabolism of Valproic acid can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Valproic acid.
Ticagrelor Ticagrelor The metabolism of Valproic acid can be decreased when combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Valproic acid.
Vandetanib Vandetanib The metabolism of Vandetanib can be decreased when combined with Valproic acid.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Valproic acid is combined with Clobazam.
Vemurafenib Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Valproic acid.
Vismodegib Vismodegib The metabolism of Vismodegib can be decreased when combined with Valproic acid.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Valproic acid.
Crizotinib Crizotinib The metabolism of Valproic acid can be decreased when combined with Crizotinib.
Cabergoline Cabergoline The metabolism of Valproic acid can be decreased when combined with Cabergoline.
Naloxone Injection Naloxone Injection The metabolism of Naloxone can be decreased when combined with Valproic acid.
Ezogabine Ezogabine The metabolism of Tiagabine can be decreased when combined with Valproic acid.
Enzalutamide Enzalutamide The metabolism of Enzalutamide can be decreased when combined with Valproic acid.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Valproic acid.
Regorafenib Regorafenib The metabolism of Valproic acid can be decreased when combined with Regorafenib.
Bosutinib Bosutinib The metabolism of Bosutinib can be decreased when combined with Valproic acid.
Teriflunomide Teriflunomide The excretion of Valproic acid can be decreased when combined with Teriflunomide.
Cabozantinib (thyroid cancer) Cabozantinib (thyroid cancer) The metabolism of Valproic acid can be decreased when combined with Cabozantinib.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Valproic acid.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Valproic acid.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Valproic acid.
Pomalidomide Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Valproic acid.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Valproic acid.
Apixaban Apixaban The metabolism of Apixaban can be decreased when combined with Valproic acid.
Dabrafenib Dabrafenib The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Ospemifene can be decreased when combined with Valproic acid.
Dolutegravir Dolutegravir The excretion of Valproic acid can be decreased when combined with Dolutegravir.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Valproic acid is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection The therapeutic efficacy of Valproic acid can be decreased when used in combination with Ertapenem.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Valproic acid is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Valproic acid.
Lomitapide Lomitapide The metabolism of Lomitapide can be decreased when combined with Valproic acid.
Ketorolac Injection Ketorolac Injection The protein binding of Ketorolac can be decreased when combined with Valproic acid.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Valproic acid.
Apremilast Apremilast The metabolism of Apremilast can be increased when combined with Valproic acid.
Ceritinib Ceritinib The metabolism of Valproic acid can be decreased when combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Valproic acid can be increased when combined with Siltuximab.
Eslicarbazepine Eslicarbazepine The metabolism of Eslicarbazepine can be decreased when combined with Valproic acid.
Belinostat Injection Belinostat Injection The metabolism of Belinostat can be decreased when combined with Valproic acid.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Valproic acid.
Testosterone Injection Testosterone Injection The excretion of Testosterone can be increased when combined with Valproic acid.
Oritavancin Injection Oritavancin Injection The metabolism of Valproic acid can be decreased when combined with Oritavancin.
Vorapaxar Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Valproic acid.
Hydrocodone Hydrocodone Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Valproic acid.
Methamphetamine Methamphetamine The risk or severity of adverse effects can be increased when Valproic acid is combined with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Valproic acid is combined with Tasimelteon.
Riociguat Riociguat The metabolism of Riociguat can be decreased when combined with Valproic acid.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Valproic acid.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Valproic acid.
Secukinumab Injection Secukinumab Injection The metabolism of Valproic acid can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Risperidone.
Palbociclib Palbociclib The metabolism of Palbociclib can be decreased when combined with Valproic acid.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Valproic acid.
Naloxegol Naloxegol The metabolism of Valproic acid can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Valproic acid can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivabradine.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Valproic acid.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Valproic acid is combined with Flibanserin.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Valproic acid.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Cariprazine.
Eluxadoline Eluxadoline The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Eluxadoline.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Valproic acid.
Trabectedin Injection Trabectedin Injection The metabolism of Valproic acid can be decreased when combined with Trabectedin.
Osimertinib Osimertinib The metabolism of Osimertinib can be decreased when combined with Valproic acid.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Valproic acid.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Valproic acid.
Rifapentine Rifapentine The metabolism of Valproic acid can be increased when combined with Rifapentine.
Lesinurad Lesinurad The metabolism of Lesinurad can be decreased when combined with Valproic acid.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Valproic acid can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Brivaracetam.
Venetoclax Venetoclax The metabolism of Venetoclax can be decreased when combined with Valproic acid.
Selexipag Selexipag The metabolism of Selexipag can be decreased when combined with Valproic acid.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Valproic acid is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
Furosemide Injection Furosemide Injection The excretion of Valproic acid can be decreased when combined with Furosemide.
Rucaparib Rucaparib The metabolism of Valproic acid can be decreased when combined with Rucaparib.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ribociclib.
Brigatinib Brigatinib The metabolism of Brigatinib can be decreased when combined with Valproic acid.
Doxepin (Insomnia) Doxepin (Insomnia) Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Deutetrabenazine.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Valproic acid is combined with Safinamide.
Edaravone Injection Edaravone Injection The excretion of Edaravone can be decreased when combined with Valproic acid.
Midostaurin Midostaurin The metabolism of Midostaurin can be decreased when combined with Valproic acid.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Valproic acid.
Enasidenib Enasidenib The metabolism of Valproic acid can be decreased when combined with Enasidenib.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be decreased when combined with Valproic acid.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Valproic acid.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Valproic acid.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Valproic acid.
Acalabrutinib Acalabrutinib The metabolism of Valproic acid can be decreased when combined with Acalabrutinib.
Letermovir Letermovir The excretion of Valproic acid can be decreased when combined with Letermovir.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The metabolism of Valproic acid can be decreased when combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Valproic acid can be increased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The metabolism of Valproic acid can be decreased when combined with Fostamatinib.
Avatrombopag Avatrombopag The excretion of Valproic acid can be decreased when combined with Avatrombopag.
Baricitinib Baricitinib The metabolism of Valproic acid can be decreased when combined with Baricitinib.
Lofexidine Lofexidine The therapeutic efficacy of Valproic acid can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Valproic acid.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Valproic acid.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Valproic acid.
Ivosidenib Ivosidenib The metabolism of Valproic acid can be decreased when combined with Ivosidenib.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Valproic acid.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Valproic acid.
Dacomitinib Dacomitinib The metabolism of Valproic acid can be decreased when combined with Dacomitinib.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Valproic acid.
Stiripentol Stiripentol The metabolism of Valproic acid can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Valproic acid.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Valproic acid.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Valproic acid.
Rifamycin Rifamycin The metabolism of Valproic acid can be increased when combined with Rifamycin.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Valproic acid.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Valproic acid can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Valproic acid is combined with Siponimod.
Acyclovir Ophthalmic Acyclovir Ophthalmic The excretion of Valproic acid can be decreased when combined with Acyclovir.
Erdafitinib Erdafitinib The metabolism of Valproic acid can be decreased when combined with Erdafitinib.
Esomeprazole Injection Esomeprazole Injection The excretion of Valproic acid can be decreased when combined with Esomeprazole.
Alpelisib Alpelisib The serum concentration of Valproic acid can be decreased when it is combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Valproic acid is combined with Solriamfetol.
Darolutamide Darolutamide The metabolism of Darolutamide can be decreased when combined with Valproic acid.
Triclabendazole Triclabendazole The metabolism of Valproic acid can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib.
Pexidartinib Pexidartinib Pexidartinib may increase the hepatotoxic activities of Valproic acid.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Valproic acid.
Pitolisant Pitolisant Pitolisant may increase the QTc-prolonging activities of Valproic acid.
Fedratinib Fedratinib The metabolism of Fedratinib can be decreased when combined with Valproic acid.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Valproic acid.
Phenytoin Injection Phenytoin Injection The serum concentration of Phenytoin can be decreased when it is combined with Valproic acid.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Fosphenytoin can be decreased when it is combined with Valproic acid.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Valproic acid.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Valproic acid.
Avapritinib Avapritinib The metabolism of Avapritinib can be decreased when combined with Valproic acid.
Lumateperone Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Valproic acid.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Lasmiditan.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Valproic acid.
Cenobamate Cenobamate The serum concentration of Valproic acid can be decreased when it is combined with Cenobamate.
Ozanimod Ozanimod The metabolism of Ozanimod can be decreased when combined with Valproic acid.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Valproic acid.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Valproic acid.
Sacituzumab govitecan-hziy Injection Sacituzumab govitecan-hziy Injection The serum concentration of Sacituzumab govitecan can be increased when it is combined with Valproic acid.
Lemborexant Lemborexant The serum concentration of Valproic acid can be decreased when it is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fenfluramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Valproic acid.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.
Pralsetinib Pralsetinib The metabolism of Valproic acid can be decreased when combined with Pralsetinib.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Valproic acid can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Valproic acid.
Cabotegravir Cabotegravir The excretion of Valproic acid can be decreased when combined with Cabotegravir.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be increased when combined with Valproic acid.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Viloxazine.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Valproic acid.
Fenoprofen Fenoprofen The protein binding of Valproic acid can be decreased when combined with Fenoprofen.
Indomethacin Indomethacin The protein binding of Valproic acid can be decreased when combined with Indomethacin.
Mefenamic Acid Mefenamic Acid The protein binding of Valproic acid can be decreased when combined with Mefenamic acid.
Naproxen Naproxen The protein binding of Valproic acid can be decreased when combined with Naproxen.
Tolmetin Tolmetin The protein binding of Valproic acid can be decreased when combined with Tolmetin.
Sulindac Sulindac The protein binding of Valproic acid can be decreased when combined with Sulindac.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Valproic acid.
Isotretinoin Isotretinoin Valproic acid may increase the Pseudotumor Cerebri activities of Isotretinoin.
Floxuridine Floxuridine The metabolism of Valproic acid can be decreased when combined with Floxuridine.
Phenobarbital Phenobarbital The serum concentration of Phenobarbital, an active metabolite of Phenobarbital, can be increased when used in combination with Valproic acid.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Valproic acid is combined with Metaxalone.
Methotrexate Injection Methotrexate Injection The metabolism of Valproic acid can be decreased when combined with Methotrexate.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Valproic acid is combined with Levorphanol.
Primidone Primidone The serum concentration of Phenobarbital, an active metabolite of Primidone, can be increased when used in combination with Valproic acid.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Valproic acid.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Valproic acid is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The serum concentration of Valproic acid can be increased when it is combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Valproic acid is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Valproic acid is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Valproic acid is combined with Clorazepic acid.
Lorazepam Lorazepam The serum concentration of Lorazepam can be increased when it is combined with Valproic acid.
Carmustine Carmustine The metabolism of Carmustine can be decreased when combined with Valproic acid.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Valproic acid.
Codeine Codeine The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Valproic acid is combined with Meprobamate.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The metabolism of Tranylcypromine can be decreased when combined with Valproic acid.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergoloid mesylate.
Tetracycline Tetracycline The excretion of Valproic acid can be decreased when combined with Tetracycline.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluoperazine.
Bleomycin Bleomycin The serum concentration of Valproic acid can be decreased when it is combined with Bleomycin.
Dapsone Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Valproic acid.
Sulfadiazine Sulfadiazine The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Sulfadiazine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Valproic acid.
Oxybutynin Oxybutynin Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Valproic acid.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Valproic acid is combined with Maprotiline.
Ibuprofen Ibuprofen The protein binding of Valproic acid can be decreased when combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Perphenazine.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Valproic acid.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluphenazine.
Phentermine Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Valproic acid.
Methylphenidate Methylphenidate The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.
Amoxapine Amoxapine The risk or severity of adverse effects can be increased when Valproic acid is combined with Amoxapine.
Sulfasalazine Sulfasalazine The serum concentration of Valproic acid can be increased when it is combined with Sulfasalazine.
Hydrocortisone Hydrocortisone The excretion of Hydrocortisone can be decreased when combined with Valproic acid.
Doxorubicin Doxorubicin The metabolism of Valproic acid can be decreased when combined with Doxorubicin.
Phenazopyridine Phenazopyridine The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Phenazopyridine.
Carbamazepine Carbamazepine The serum concentration of carbamazepine-10,11­ epoxide (CBZ-E), an active metabolite of Carbamazepine, can be increased when used in combination with Valproic acid.
Molindone Molindone The risk or severity of adverse effects can be increased when Valproic acid is combined with Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Valproic acid.
Cimetidine Cimetidine The excretion of Cimetidine can be decreased when combined with Valproic acid.
Warfarin Warfarin The serum concentration of Warfarin can be increased when it is combined with Valproic acid.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Valproic acid is combined with Clonazepam.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Valproic acid.
Promethazine Promethazine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Meclofenamate Meclofenamate The protein binding of Valproic acid can be decreased when combined with Meclofenamic acid.
Nitrofurantoin Nitrofurantoin The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitrofurantoin.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Valproic acid.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Valproic acid is combined with Loxapine.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Valproic acid.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Quinine.
Ethosuximide Ethosuximide The serum concentration of Valproic acid can be decreased when it is combined with Ethosuximide.
Triamterene Triamterene The metabolism of Triamterene can be decreased when combined with Valproic acid.
Sulfinpyrazone Sulfinpyrazone The metabolism of Valproic acid can be decreased when combined with Sulfinpyrazone.
Isosorbide Isosorbide The metabolism of Isosorbide can be increased when combined with Valproic acid.
Secobarbital Secobarbital The serum concentration of Secobarbital can be increased when it is combined with Valproic acid.
Desipramine Desipramine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Valproic acid.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imipramine.
Probenecid Probenecid The metabolism of Valproic acid can be decreased when combined with Probenecid.
Quinidine Quinidine The metabolism of Valproic acid can be decreased when combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Procainamide.
Isoniazid Isoniazid The metabolism of Valproic acid can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Valproic acid can be increased when combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Valproic acid can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital The serum concentration of Valproic acid can be increased when it is combined with Butabarbital.
Levothyroxine Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Valproic acid.
Liothyronine Liothyronine The excretion of Valproic acid can be decreased when combined with Liothyronine.
Methimazole Methimazole The metabolism of Valproic acid can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Valproic acid.
Tolbutamide Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Valproic acid.
Tolazamide Tolazamide The metabolism of Tolazamide can be decreased when combined with Valproic acid.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextromethorphan.
Dinoprostone Dinoprostone The excretion of Valproic acid can be decreased when combined with Dinoprostone.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Valproic acid is combined with Cyclobenzaprine.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Valproic acid.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Valproic acid.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Valproic acid.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Valproic acid.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic acid.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Valproic acid is combined with Meclizine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Valproic acid.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Valproic acid is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Valproic acid.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Valproic acid is combined with Methocarbamol.
Folic Acid Folic Acid The serum concentration of Folic acid can be decreased when it is combined with Valproic acid.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Valproic acid.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Valproic acid.
Minoxidil Minoxidil The metabolism of Minoxidil can be decreased when combined with Valproic acid.
Pseudoephedrine Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Pseudoephedrine.
Nortriptyline Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Valproic acid.
Amphotericin B Injection Amphotericin B Injection The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.
Mercaptopurine Mercaptopurine The excretion of Valproic acid can be decreased when combined with Mercaptopurine.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Valproic acid is combined with Nalbuphine.
Allopurinol Allopurinol The excretion of Allopurinol can be decreased when combined with Valproic acid.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Valproic acid is combined with Trimethobenzamide.
Flavoxate Flavoxate Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.
Fluorouracil Injection Fluorouracil Injection The metabolism of Valproic acid can be decreased when combined with Fluorouracil.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Valproic acid.
Cefaclor Cefaclor The excretion of Valproic acid can be decreased when combined with Cefaclor.
Cefadroxil Cefadroxil The excretion of Valproic acid can be decreased when combined with Cefadroxil.
Cefazolin Injection Cefazolin Injection The excretion of Valproic acid can be decreased when combined with Cefazolin.
Cephalexin Cephalexin The excretion of Valproic acid can be decreased when combined with Cephalexin.
Dacarbazine Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Valproic acid.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Valproic acid is combined with Acetazolamide.
Cefotaxime Injection Cefotaxime Injection The excretion of Valproic acid can be decreased when combined with Cefotaxime.
Ketoconazole Ketoconazole The metabolism of Valproic acid can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Valproic acid is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The metabolism of Valproic acid can be decreased when combined with Thiotepa.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Valproic acid.
Captopril Captopril The excretion of Captopril can be decreased when combined with Valproic acid.
Vinblastine Vinblastine The metabolism of Vinblastine can be decreased when combined with Valproic acid.
Metoprolol Metoprolol The metabolism of Metoprolol can be decreased when combined with Valproic acid.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Valproic acid.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiothixene.
Aspirin Aspirin The metabolism of Valproic acid can be decreased when combined with Acetylsalicylic acid.
Salsalate Salsalate The protein binding of Valproic acid can be decreased when combined with Salsalate.
Chlorambucil Chlorambucil The therapeutic efficacy of Valproic acid can be decreased when used in combination with Chlorambucil.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Valproic acid.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Valproic acid.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Valproic acid is combined with Triazolam.
Dicyclomine Dicyclomine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Valproic acid.
Propantheline Propantheline Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Valproic acid.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Valproic acid.
Nifedipine Nifedipine Nifedipine may increase the hypotensive activities of Valproic acid.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Valproic acid.
Verapamil Verapamil The metabolism of Verapamil can be decreased when combined with Valproic acid.
Pindolol Pindolol The risk or severity of adverse effects can be increased when Valproic acid is combined with Pindolol.
Cisplatin Injection Cisplatin Injection The metabolism of Valproic acid can be decreased when combined with Cisplatin.
Diflunisal Diflunisal The serum concentration of Valproic acid can be increased when it is combined with Diflunisal.
Piroxicam Piroxicam The protein binding of Valproic acid can be decreased when combined with Piroxicam.
Bumetanide Bumetanide The excretion of Valproic acid can be decreased when combined with Bumetanide.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Valproic acid.
Glyburide Glyburide The metabolism of Glyburide can be decreased when combined with Valproic acid.
Glipizide Glipizide The metabolism of Glipizide can be decreased when combined with Valproic acid.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Valproic acid.
Pentoxifylline Pentoxifylline Valproic acid may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Valproic acid.
Ceftriaxone Injection Ceftriaxone Injection The excretion of Valproic acid can be decreased when combined with Ceftriaxone.
Labetalol Labetalol The metabolism of Labetalol can be decreased when combined with Valproic acid.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.
Gemfibrozil Gemfibrozil The metabolism of Valproic acid can be decreased when combined with Gemfibrozil.
Guanabenz Guanabenz The metabolism of Guanabenz can be decreased when combined with Valproic acid.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic The excretion of Adefovir dipivoxil can be decreased when combined with Valproic acid.
Ketoprofen Ketoprofen The protein binding of Valproic acid can be decreased when combined with Ketoprofen.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Valproic acid.
Enalapril Enalapril The excretion of Valproic acid can be decreased when combined with Enalapril.
Flurbiprofen Flurbiprofen The protein binding of Valproic acid can be decreased when combined with Flurbiprofen.
Amiodarone Amiodarone The metabolism of Amiodarone can be decreased when combined with Valproic acid.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Buspirone.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Valproic acid.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Valproic acid.
Mesalamine Mesalamine The serum concentration of Valproic acid can be increased when it is combined with Mesalazine.
Diclofenac Diclofenac The protein binding of Valproic acid can be decreased when combined with Diclofenac.
Fluoxetine Fluoxetine The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Valproic acid.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Valproic acid is combined with Estazolam.
Idarubicin Idarubicin The metabolism of Idarubicin can be decreased when combined with Valproic acid.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Valproic acid.
Didanosine Didanosine The excretion of Didanosine can be decreased when combined with Valproic acid.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Valproic acid.
Etodolac Etodolac The protein binding of Valproic acid can be decreased when combined with Etodolac.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Valproic acid.
Nabumetone Nabumetone The protein binding of Valproic acid can be decreased when combined with Nabumetone.
Pravastatin Pravastatin The excretion of Valproic acid can be decreased when combined with Pravastatin.
Quinapril Quinapril The excretion of Quinapril can be decreased when combined with Valproic acid.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Valproic acid.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valproic acid.
Teniposide Injection Teniposide Injection The metabolism of Teniposide can be decreased when combined with Valproic acid.
Itraconazole Itraconazole The metabolism of Valproic acid can be decreased when combined with Itraconazole.
Oxaprozin Oxaprozin The protein binding of Valproic acid can be decreased when combined with Oxaprozin.
Atovaquone Atovaquone The metabolism of Valproic acid can be decreased when combined with Atovaquone.
Rifabutin Rifabutin The metabolism of Valproic acid can be increased when combined with Rifabutin.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sotalol.
Zolpidem Zolpidem Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The metabolism of Doxazosin can be decreased when combined with Valproic acid.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Valproic acid.
Omeprazole Omeprazole The metabolism of Omeprazole can be decreased when combined with Valproic acid.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Valproic acid is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Valproic acid.
Venlafaxine Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Valproic acid.
Stavudine Stavudine The excretion of Stavudine can be decreased when combined with Valproic acid.
Famciclovir Famciclovir The metabolism of Famciclovir can be decreased when combined with Valproic acid.
Fluvoxamine Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Valproic acid.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Valproic acid is combined with Nefazodone.
Lamotrigine Lamotrigine Valproic acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Valproic acid.
Valacyclovir Valacyclovir The excretion of Valaciclovir can be decreased when combined with Valproic acid.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Vinorelbine can be decreased when combined with Valproic acid.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Valproic acid.
Lansoprazole Lansoprazole The metabolism of Valproic acid can be decreased when combined with Lansoprazole.
Alprostadil Urogenital Alprostadil Urogenital The excretion of Alprostadil can be decreased when combined with Valproic acid.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Valproic acid.
Nicardipine Nicardipine The metabolism of Nicardipine can be decreased when combined with Valproic acid.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Valproic acid is combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Valproic acid can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Valproic acid.
Lamivudine Lamivudine The excretion of Lamivudine can be decreased when combined with Valproic acid.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Valproic acid is combined with Riluzole.
Glimepiride Glimepiride The metabolism of Glimepiride can be decreased when combined with Valproic acid.
Anastrozole Anastrozole The metabolism of Valproic acid can be decreased when combined with Anastrozole.
Indinavir Indinavir The metabolism of Valproic acid can be decreased when combined with Indinavir.
Ritonavir Ritonavir The metabolism of Valproic acid can be increased when combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Valproic acid.
Cidofovir Injection Cidofovir Injection The excretion of Cidofovir can be decreased when combined with Valproic acid.
Meropenem Injection Meropenem Injection The therapeutic efficacy of Valproic acid can be decreased when used in combination with Meropenem.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Valproic acid.
Zafirlukast Zafirlukast The metabolism of Valproic acid can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Valproic acid may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Valproic acid.
Zileuton Zileuton The metabolism of Zileuton can be decreased when combined with Valproic acid.
Valsartan Valsartan The metabolism of Valsartan can be decreased when combined with Valproic acid.
Pramipexole Pramipexole Valproic acid may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Valproic acid is combined with Donepezil.
Nelfinavir Nelfinavir The metabolism of Valproic acid can be increased when combined with Nelfinavir.
Fexofenadine Fexofenadine The excretion of Valproic acid can be decreased when combined with Fexofenadine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Valproic acid.
Carvedilol Carvedilol The metabolism of Carvedilol can be decreased when combined with Valproic acid.
Nilutamide Nilutamide The metabolism of Valproic acid can be decreased when combined with Nilutamide.
Flutamide Flutamide The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Flutamide.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Valproic acid is combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Valproic acid.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Valproic acid is combined with Sertraline.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Valproic acid.
Letrozole Letrozole The metabolism of Valproic acid can be decreased when combined with Letrozole.
Raloxifene Raloxifene The metabolism of Valproic acid can be decreased when combined with Raloxifene.
Irbesartan Irbesartan The metabolism of Irbesartan can be decreased when combined with Valproic acid.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Valproic acid is combined with Ropinirole.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Valproic acid.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Valproic acid is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Valproic acid is combined with Tolcapone.
Citalopram Citalopram Valproic acid may increase the QTc-prolonging activities of Citalopram.
Capecitabine Capecitabine The metabolism of Valproic acid can be decreased when combined with Capecitabine.
Efavirenz Efavirenz The metabolism of Valproic acid can be increased when combined with Efavirenz.
Abacavir Abacavir The metabolism of Abacavir can be decreased when combined with Valproic acid.
Sildenafil Sildenafil The metabolism of Sildenafil can be decreased when combined with Valproic acid.
Pioglitazone Pioglitazone The metabolism of Valproic acid can be decreased when combined with Pioglitazone.
Celecoxib Celecoxib The protein binding of Valproic acid can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Valproic acid.
Tolterodine Tolterodine Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir The excretion of Oseltamivir can be decreased when combined with Valproic acid.
Balsalazide Balsalazide The serum concentration of Valproic acid can be increased when it is combined with Balsalazide.
Nateglinide Nateglinide The metabolism of Nateglinide can be decreased when combined with Valproic acid.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Valproic acid.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Valproic acid is combined with Levetiracetam.
Rabeprazole Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Valproic acid.
Terbinafine Terbinafine The metabolism of Terbinafine can be decreased when combined with Valproic acid.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists

Still Confused? Ask the pharmacist a question here!